Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Using Reimbursement to Drive Innovation in Tumor Biomarker Tests

Key clinical point: Improved reimbursement for tumor biomarker tests can spur innovation.

Major finding: Tumor biomarker tests are currently undervalued.

Study details: Authors suggest a three-tiered, value-based system that will help drive the development of better tumor biomarker tests.

Disclosures: Research was supported by a grant from AHRQ and from Fashion Footwear Charitable Foundation of New York/QVC Presents Shoes on Sale. All authors reported financial ties to one or more pharmaceutical companies.

Citation:

Michaela Dinan et al. JCO Precis Oncol. 2019 Sep 18. doi: 10.1200/PO.19.00210.